Title:
ENGINEERED T CELL RECEPTORS AND USES THEREOF
Document Type and Number:
WIPO Patent Application WO/2021/030153
Kind Code:
A3
Abstract:
The invention relates to fusion proteins comprising a transmembrane domain and an intracellular domain capable of providing a stimulatory signal, and engineered T cell receptors comprising same. The disclosure provides, in part, engineered T cell receptors (TCR) comprising one or more signaling domain(s) fused to the intracellular portion of at least one TCR subunit.
Inventors:
OH JULYUN (US)
YI CHANG (US)
WARSHAVIAK DORA (US)
MOCK JEE (US)
DARIS MARK (US)
HAMBURGER AGNES (US)
JOHNSTON JAMES (US)
KAMB CARL (US)
MARTIN AARON (US)
YI CHANG (US)
WARSHAVIAK DORA (US)
MOCK JEE (US)
DARIS MARK (US)
HAMBURGER AGNES (US)
JOHNSTON JAMES (US)
KAMB CARL (US)
MARTIN AARON (US)
Application Number:
PCT/US2020/045250
Publication Date:
March 25, 2021
Filing Date:
August 06, 2020
Export Citation:
Assignee:
A2 BIOTHERAPEUTICS INC (US)
International Classes:
C07K14/705
Domestic Patent References:
| WO2018067993A1 | 2018-04-12 | |||
| WO2018193231A1 | 2018-10-25 | |||
| WO2010039899A2 | 2010-04-08 | |||
| WO2019067677A1 | 2019-04-04 | |||
| WO2017096327A2 | 2017-06-08 |
Foreign References:
| US20180010095A1 | 2018-01-11 | |||
| US20130266551A1 | 2013-10-10 | |||
| US20160311901A1 | 2016-10-27 | |||
| US20190022216A1 | 2019-01-24 | |||
| US20190240304A1 | 2019-08-08 |
Other References:
COURTNEY ADAM H., LO WAN-LIN, WEISS ARTHUR: "TCR SIGNALING: MECHANISMS OF INITIATION AND PROPAGATION", TRENDS IN BIOCHEMICAL SCIENCES, vol. 43, no. 2, February 2018 (2018-02-01), pages 108 - 123, XP055805438, DOI: 10.1016/j.tibs.2017.11.008
Attorney, Agent or Firm:
CHRISTIANSEN II, William, T. et al. (US)
Download PDF: